Rhumbline Advisers Purchases 3,468 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

Rhumbline Advisers lifted its position in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 10.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,101 shares of the company’s stock after buying an additional 3,468 shares during the quarter. Rhumbline Advisers owned approximately 0.11% of Sera Prognostics worth $294,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sanders Morris Harris LLC lifted its stake in Sera Prognostics by 165.7% in the fourth quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company’s stock worth $725,000 after acquiring an additional 56,500 shares during the period. Pallas Capital Advisors LLC purchased a new stake in shares of Sera Prognostics in the 4th quarter worth approximately $113,000. JPMorgan Chase & Co. boosted its stake in shares of Sera Prognostics by 7,357.8% during the third quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock valued at $6,902,000 after purchasing an additional 873,002 shares in the last quarter. Barclays PLC increased its holdings in Sera Prognostics by 321.6% during the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after buying an additional 30,093 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Sera Prognostics by 8.9% during the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock valued at $4,578,000 after buying an additional 47,969 shares during the period. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Stock Up 4.1 %

Sera Prognostics stock opened at $4.32 on Monday. The firm has a market cap of $145.90 million, a P/E ratio of -4.36 and a beta of 0.89. The business has a fifty day moving average of $5.70 and a two-hundred day moving average of $6.77. Sera Prognostics, Inc. has a twelve month low of $3.84 and a twelve month high of $12.36.

Insider Transactions at Sera Prognostics

In other news, General Counsel Benjamin Jackson sold 13,272 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $7.42, for a total value of $98,478.24. Following the sale, the general counsel now directly owns 128,473 shares in the company, valued at approximately $953,269.66. This trade represents a 9.36 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joshua Phillips sold 12,163 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57. Following the transaction, the director now owns 2 shares of the company’s stock, valued at approximately $12.78. This trade represents a 99.98 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 69,877 shares of company stock valued at $480,677. Corporate insiders own 15.80% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.